Company: HURA
Filing Date: 2025-08-12
Form Type: S-1
Source: 0001193125-25-179009
Chunk: 247

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-08-12
Form: S-1
Chunk 247
---
 taxes and the applicable statutory federal income tax rate of the jurisdiction of domicile using specific categories, including separate disclosure for any reconciling items within certain categories that are equal to or greater than a specified quantitative threshold of 5%. ASU 2023-09also requires disclosure of, on an annual basis, the year-to-dateamount of income taxes paid (net of refunds received) disaggregated by federal, state, and foreign jurisdictions, including additional disaggregated information on income taxes paid (net of refunds received) to an individual jurisdiction equal to or greater than 5% of total income taxes paid (net of refunds received). The amendments in ASU2023-09are effective for annual periods beginning after December 15, 2024, and should be applied prospectively. The Company is currently evaluating the impact of the update on the Company’s consolidated financial statements and related disclosures. F-1 5

Except as disclosed elsewhere, there have been no new, or existing, recently issued accounting pronouncements that are of significance, or potential significance, that impact the Company’s consolidated financial statements. 3. Clinical trial deposit In October 2020, the Company announced that it had entered into a final agreement with a contract research organization (“CRO”) for the management of the Company’s registrational study of VAL-083for glioblastoma. Under the agreement, the Company supplied the drug for the study and the CRO managed all operational aspects of the study including site activation and patient enrollment. The Company was required to make certain payments under the agreement related to patient enrollment milestones. For the year ended June 30, 2024, the Company has recognized an expense of $ 563(2023 - $ 5,065), respectively, for this study in relation to clinical site initiation and patient enrollment. On October 31, 2023, the Company announced that preliminary topline results from this registrational study for VAL-083did not perform better than the current standards of care in glioblastoma. As a result, the Company announced that it has terminated the development of VAL-083.In the year ended June 30, 2024, the remaining deposit of $ 1,075was offset against amounts owing to the CRO and the agreement with the CRO was terminated with an additional final cost of $ 1,000, which was paid in the year ended June 30, 2024. In the year ended June 30, 2024, the Company recorded $ 205as a deposit